News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
| IDRA [NASD] https://www.otcmarkets.com/stock/IDRA/overview |
| Idera Pharmaceuticals, Inc. |
We’re devoted to redefining the treatment of cancer and rare diseases where serious unmet needs exist.
https://www.iderapharma.com/our-company/
https://www.iderapharma.com/who-we-help/
https://www.iderapharma.com/our-approach/toll-like-receptor-immune-modulation/
Toll-like receptors (TLRs) are a class of proteins that are an important part of the innate immune system.
They alert the body to potential danger by recognizing pieces of bacteria, viruses, or damaged cells.
They essentially act like a smoke alarm, warning the body when trouble is detected.
Our lead investigational agent, tilsotolimod, activates TLR9. In cancer patients with solid tumors,
tilsotolimod is injected directly into a tumor to trigger TLR9 into action and prime a local immune response to help attack the tumor.
This has been demonstrated in pre-clinical models, and our translational studies during early clinical trials have shown rapid immune
activation in the injected tumor along with systemic increases in T cells.
Idera is investigating the combination of tilsotolimod with checkpoint inhibitors and other immune activators with the aim of providing improved outcomes for patients in need.
https://www.iderapharma.com/our-approach/key-publications/
https://www.iderapharma.com/areas-of-focus/oncology/immuno-oncology/
https://www.iderapharma.com/pipeline-programs/
| TUMOR TYPE |
| |||||||
|---|---|---|---|---|---|---|---|---|
| Anti-PD-1 Refractory Advanced Melanoma |
| |||||||
| Microsatellite-Stable Colorectal Cancer |
| |||||||
| Resistant Solid Tumors |
| |||||||
| Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma |
|
1 Tilsotolimod is an investigational agent which has not been approved by any regulatory authority
| IDRA [NASD] |
| Idera Pharmaceuticals, Inc. |
| Healthcare | Biotechnology | USA |
| Shs Outstand | 41.19M |
| Shs Float | 38.72M ,
|
| 52W Range | 0.97 - 6.14 |
| 52W High | -81.76% |
| Insider Own | 1.30% |
| Inst Own | 19.70% |
| Book/sh | 1.03 |
| Cash/sh | 0.84 |
| Employees | 32 |
| Debt/Eq | 0.00 no short term either |
The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9,
such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400.
The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis.
It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication.
IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company
or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial.
The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.
In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens.
It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs,
are nucleic acid-based and represent a novel approach to selectively, silence gene expression.
It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents.
In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer,
it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies,
and TLR3 agonists for use as vaccine adjuvants.
IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection.
The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection,
one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin,
an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection.
In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers.
Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies.
In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.
The Company competes with Dynavax Technologies Corporation,
GlaxoSmithKline plc.,
Pfizer, Inc.,
VentiRx Pharmaceuticals.,
Novartis,
Dynavax Technologies Corporation,
VaxInnate, Inc.,
Intercell AG,
Cytos Biotechnology AG and
Celldex Therapeutics, Inc.
| PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
